| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.29 | 0.01 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |